- Gilead Sciences' quarterly earnings surpassed expectations despite a slight revenue decline.
- Analysts project a modest upside for Gilead's stock, with varied price targets.
- GuruFocus estimates a potential downside risk based on the GF Value calculation.
Gilead Sciences (GILD, Financial) recently reported its first-quarter 2025 financial results, showcasing a non-GAAP EPS of $1.81, which outperformed market expectations by $0.04. However, the company experienced a slight 0.3% decline in revenue, bringing in $6.67 billion, which fell $140 million short of forecasts. Noteworthy was the growth in sales of Gilead's HIV and Liver Disease segments, which helped mitigate the downtrend in Veklury and Oncology sales.
Analyst Price Forecasts
Wall Street analysts have set their sights on Gilead Sciences Inc (GILD, Financial), issuing one-year price targets that average out to $112.27. This figure is derived from the assessments of 24 analysts, with projections ranging from a high of $140.00 to a low of $82.00. The current analysis suggests an approximate upside potential of 5.77% compared to the existing stock price of $106.15. For more in-depth estimation data, explore the Gilead Sciences Inc (GILD) Forecast page.
Brokerage Ratings and Recommendations
The consensus from 30 brokerage firms places Gilead Sciences Inc's (GILD, Financial) average brokerage recommendation at 2.1, an indicator of "Outperform" on the current rating scale. Within this scale, a rating of 1 denotes a Strong Buy, whereas 5 indicates a Sell. This suggests confidence in the company's potential for growth and performance.
GF Value Insight
According to GuruFocus, the estimated GF Value for Gilead Sciences Inc (GILD, Financial) in the upcoming year stands at $80.51, indicating a potential downside of 24.15% from the present price of $106.15. The GF Value is GuruFocus's calculated fair value based on the historical trading multiples of the stock, coupled with past growth and future performance estimates. For comprehensive data and analysis, please visit the Gilead Sciences Inc (GILD) Summary page.
